The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women

Launched by TONGJI HOSPITAL · Aug 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new injection called FRD001 to see if it helps doctors better identify whether ovarian masses (growths on the ovaries) are cancerous (malignant) or not (benign) during ultrasound imaging. The researchers aim to find out if using FRD001 can improve the accuracy of ultrasound tests compared to standard methods. Women aged 18 to 75 with specific types of ovarian masses who are in good health may be eligible to participate.

Participants in the study will first receive a standard ultrasound examination and then have the FRD001 injection before a second ultrasound. This trial will help determine if FRD001 can make a significant difference in diagnosing ovarian masses, which is important for making treatment decisions. Throughout the trial, safety will be monitored, and participants will have regular check-ins to ensure their well-being. If you have any concerns or questions about participating, it's encouraged to discuss them with your healthcare provider.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• All participants must meet the following inclusion criteria to be eligible for enrollment in this study:
• • Female participants aged 18 to 75 years (inclusive of the age limits);
• • Patients with untreated unilateral or bilateral, unilocular or multilocular cystic/solid masses;
• • Expected survival of at least 3 months;
• • ECOG performance status of 0 to 2 for participants with malignant tumors;
• • Organ function levels must meet the following requirements: a. Hematology: WBC ≥ 3 × 10\^9/L, ANC ≥ 1.5 × 10\^9/L, Hb ≥ 90 g/L, PLT ≥ 75 × 10\^9/L; b. Liver function: TBIL ≤ 1.5 × ULN, ALT and AST ≤ 3 × ULN (≤ 5 × ULN for patients with liver metastases); c. Kidney function: Cr ≤ 1.5 × ULN; d. Coagulation function: Prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN, International normalized ratio (INR) ≤ 1.5 × ULN; e. Electrolytes: Corrected magnesium ≥ LLN, with allowance for correction of electrolytes during screening; f. Cardiac function: Left ventricular ejection fraction ≥ 50%; g. Pulse oximetry ≥ 93%;
• • Women of childbearing potential must use effective contraception during the study (effective contraceptive methods include sterilization, intrauterine hormonal devices, condoms, contraceptive pills/devices, abstinence, or vasectomy);
• • Participants must fully understand the purpose, nature, methods, and potential adverse reactions of the trial, voluntarily agree to participate, and sign a written informed consent form, demonstrating the ability to adhere to the protocol requirements to complete the study.
• Exclusion Criteria:
• Participants who meet any of the following criteria are not eligible for enrollment:
• • Patients with benign teratomas;
• • Patients who have undergone total removal of the uterine appendages;
• • Patients with congenital malformations of the reproductive system;
• • Patients who have received radiotherapy, chemotherapy, or invasive procedures (including but not limited to radiofrequency ablation) during the administration of the investigational medicinal product (IMP) and the confirmatory diagnostic examination;
• • Women planning to become pregnant within 6 months, currently pregnant, or breastfeeding, or women of childbearing potential with a positive pregnancy test during the screening period;
• • Individuals allergic to the components of FRD001 injection or with a history of other severe allergies;
• • Insufficient acoustic window indicated by ultrasound examination during screening or prior examinations;
• • Presence of contraindications for imaging examinations related to the study protocol;
• • Conditions such as adult respiratory distress syndrome, severe emphysema, pulmonary vasculitis, or pulmonary embolism;
• • Severe cardiovascular or cerebrovascular diseases, including but not limited to: a. Significant cardiac rhythm or conduction abnormalities that require clinical intervention, such as ventricular arrhythmias, second- to third-degree atrioventricular block, or QTc interval ≥ 450 ms; b. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other cardiovascular events of grade 3 or higher within 6 months prior to the first dose; c. New York Heart Association (NYHA) functional classification ≥ II or left ventricular ejection fraction (LVEF) \< 50%;
• • Known severe pulmonary hypertension or uncontrolled systemic hypertension; uncontrolled hypertension (for individuals \<60 years old, systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg; for individuals ≥ 60 years old, systolic blood pressure ≥ 150 mmHg and diastolic blood pressure ≥ 90 mmHg);
• • Patients with symptomatic brain metastases requiring treatment;
• • Individuals with severe or uncontrolled mental illness;
• • Presence of active infections requiring systemic treatment or uncontrolled infections within 14 days prior to starting the investigational drug;
• • Positive tests for antibodies to human immunodeficiency virus (HIV), hepatitis C virus (HCV), or Treponema pallidum; positive hepatitis B virus (HBV) surface antigen;
• • History of right-to-left, bidirectional, or transient right-to-left cardiac shunts;
• • History of alcohol or drug abuse/dependence;
• • Participation in other clinical trials involving investigational drugs within 30 days prior to screening;
• • Any medications or treatments deemed by the investigator to potentially interfere with trial data or cause severe side effects that have not been fully washed out prior to enrollment;
• • Any other conditions deemed inappropriate for participation in this clinical trial by the investigator.